A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Trial Profile

A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GSK 2696275 (Primary)
  • Indications Wiskott-Aldrich syndrome
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms TIGET-WAS
  • Most Recent Events

    • 22 Apr 2017 Planned End Date changed from 1 Apr 2023 to 31 Mar 2023.
    • 05 Dec 2015 According to a media release, data from this study will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 2015.
    • 10 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top